Form 4: Ligand Pharmaceuticals CFO Octavio Espinoza Reports Stock Acquisition

Octavio Espinoza, CFO of Ligand Pharmaceuticals, reports acquiring 267 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• On June 28, 2024, Octavio Espinoza, the Chief Financial Officer of Ligand Pharmaceuticals, acquired 267 shares of common stock.
• The acquisition was made through the Ligand Employee Stock Purchase Plan at a price of $60.707 per share.
• Following the transaction, Espinoza directly owns 23,646 shares of Ligand Pharmaceuticals.
• The transaction was exempt under Rule 16b-3(d) and Rule 16b-3(c).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction under an employee stock purchase plan, indicating standard company operations.

Positives

• The CFO's participation in the Employee Stock Purchase Plan could be seen as a positive signal, indicating confidence in the company's future.

Industry Context

Insider transactions are routinely monitored and reported to the SEC. This transaction is a routine acquisition under an employee stock purchase plan.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it's a routine acquisition of shares by an executive.

Key Dates